Progress in TakeAim Lymphoma Study
The TakeAim Lymphoma study, evaluating emavusertib in combination with ibrutinib, is progressing well with collaborative discussions with the FDA and EMA. The study aims for accelerated submissions in the U.S. and Europe with plans to enroll 30 to 40 additional patients.
Positive Data in AML and MDS
Emavusertib showed a 38% composite CR rate in AML with FLT3 mutation, compared to 21% for gilteritinib. The drug's novel mechanism of action is promising for further studies, including a registrational study in AML and a combination study in high-risk MDS.
Productive Financial Management
Net loss decreased to $8.6 million from $11.8 million year-over-year, and research and development expenses decreased significantly, contributing to a cash runway extending into the first quarter of 2026.